Insulet Corporation $PODD Shares Bought by Integrated Wealth Concepts LLC

Integrated Wealth Concepts LLC raised its holdings in Insulet Corporation (NASDAQ:PODD) by 2.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,635 shares of the medical instruments supplier’s stock after purchasing an additional 73 shares during the period. Integrated Wealth Concepts LLC’s holdings in Insulet were worth $955,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Brooklyn Investment Group raised its position in shares of Insulet by 7.0% during the 1st quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier’s stock valued at $209,000 after acquiring an additional 52 shares in the last quarter. OLD National Bancorp IN raised its position in shares of Insulet by 6.7% during the 1st quarter. OLD National Bancorp IN now owns 880 shares of the medical instruments supplier’s stock valued at $231,000 after acquiring an additional 55 shares in the last quarter. Cooper Financial Group raised its position in shares of Insulet by 5.7% during the 1st quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier’s stock valued at $283,000 after acquiring an additional 58 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its position in shares of Insulet by 23.1% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 314 shares of the medical instruments supplier’s stock valued at $82,000 after acquiring an additional 59 shares in the last quarter. Finally, HighTower Advisors LLC raised its position in shares of Insulet by 2.1% during the 1st quarter. HighTower Advisors LLC now owns 2,882 shares of the medical instruments supplier’s stock valued at $757,000 after acquiring an additional 60 shares in the last quarter.

Insulet Price Performance

Shares of PODD opened at $337.94 on Friday. The firm has a market capitalization of $23.79 billion, a price-to-earnings ratio of 102.72, a price-to-earnings-growth ratio of 2.80 and a beta of 1.36. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. Insulet Corporation has a one year low of $225.28 and a one year high of $353.50. The stock’s fifty day moving average is $310.77 and its 200-day moving average is $291.47.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.25. The company had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company’s quarterly revenue was up 32.9% compared to the same quarter last year. During the same period last year, the company earned $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Insider Activity

In other Insulet news, SVP Prem Singh sold 687 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares in the company, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.39% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on PODD shares. Wall Street Zen raised Insulet from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. The Goldman Sachs Group started coverage on Insulet in a research report on Friday, May 30th. They set a “buy” rating and a $380.00 price target on the stock. Morgan Stanley reissued an “overweight” rating on shares of Insulet in a research report on Thursday, August 7th. Raymond James Financial reissued an “outperform” rating and set a $360.00 price target (up from $328.00) on shares of Insulet in a research report on Tuesday, May 27th. Finally, Barclays upped their price target on Insulet from $266.00 to $300.00 and gave the company an “equal weight” rating in a research report on Thursday, August 21st. Sixteen equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $335.12.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.